58 Biggest Movers From Yesterday
Gainers
Adagio Therapeutics, Inc. (NASDAQ: ADGI) shares jumped 123.3% to settle at $14.18 on Thursday after traders circulated rumors of a reiterated Buy rating and $46 price target from Jefferies.
Raymond James Downgrades uniQure to Outperform, Lowers Price Target to $58
Raymond James analyst Danielle Brill downgrades uniQure (NASDAQ:QURE) from Strong Buy to Outperform and lowers the price target from $75 to $58.
UniQure Shares Fall After Clinical Update From Huntington’s Disease Gene Therapy Trial
UniQure NV (NASDAQ: QURE)
Mid-Day Market Update: Gold Rises 2%; IronNet Shares Plummet
Midway through trading Thursday, the Dow traded up 0.67% to 36,166.39 while the NASDAQ fell 0.63% to 15,467.79. The S&P also rose, gaining 0.20% to 4,719.09.
Mid-Morning Market Update: Markets Mixed; Accenture Beats Q1 Estimates
Following the market opening Thursday, the Dow traded up 0.49% to 36,102.31 while the NASDAQ fell 0.68% to 15,460.25. The S&P also rose, gaining 0.08% to 4,713.43.
uniQure Announces Clinical Update On First Patients In Phase I/II Clinical Trial Of AMT-130 Gene Therapy For The Treatment Of Huntington’s Disease
~ Treatment was well tolerated with no significant safety issues
related to AMT-130 in first two treated patients through one year of follow-up ~
~ Neurofilament Light Chain (NfL) rose as expected immediately following
CSL Behring, UniQure’s Hemophilia B Gene Therapy Hits Primary Endpoint
CSL Behring and uniQure N.V.'s (NASDAQ: QURE) etranacogene dezaparvovec, a hemophilia B gene therapy, achieved the pre-specified
Director Of Uniqure Sold $164.75 Thousand In Stock
Robert Gut, Director at Uniqure (NASDAQ:QURE), made a large insider sell on September 21, according to a new SEC filing.